UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM N-CSR
CERTIFIED SHAREHOLDER REPORT OF REGISTERED
MANAGEMENT INVESTMENT COMPANIES
Investment Company Act file number (811-23823)
Tema ETF Trust
(Exact name of registrant as specified in charter)
Brookfield Place
200 Vesey Street, Suite 24106
New York, NY 10281
(Address of principal executive offices) (Zip code)
Matthew Keeling, President
Brookfield Place
200 Vesey Street, Suite 24106
New York, NY 10281
(Name and address of agent for service)
(302) - 499 - 4928 ext. 801
Registrant’s telephone number, including area code
Date of fiscal year end: February 28
Date of reporting period: August 31, 2024
Item 1. Reports to Stockholders.
(a)
 | Tema American Reshoring ETF |  |
RSHO (Principal U.S. Listing Exchange: NYSE Arca, Inc.)NYSEArca | ||
| Semi-Annual Shareholder Report | August 31, 2024 |
Fund Name | Costs of a $10,000 investment | Costs paid as a percentage of a $10,000 investment* |
| Tema American Reshoring ETF | $39 | 0.75% |
| * | Annualized. |
Net Assets | $101,507,085 |
Number of Holdings | 31 |
Portfolio Turnover | 4% |
Top 10 Issuers | (% of net assets) |
Applied Industrial Technologies, Inc. | 5.3% |
Eaton Corp. PLC | 4.9% |
Clean Harbors, Inc. | 4.9% |
SPX Technologies, Inc. | 4.6% |
Linde PLC | 4.4% |
CRH PLC | 4.4% |
Ingersoll Rand, Inc. | 4.3% |
Primoris Services Corp. | 4.1% |
Fluor Corp. | 3.7% |
Federal Signal Corp. | 3.6% |
Top Sectors* | (% of net assets) |
Industrials | 70.7% |
Materials | 18.5% |
Health Care | 6.3% |
Consumer Discretionary | 2.5% |
Information Technology | 1.3% |
Cash & Other | 0.7% |
| * | The Global Industry Classification Standard (“GICS®”) was developed by and/or is the exclusive property of MSCI, Inc. (“MSCI”) and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. |
| Tema American Reshoring ETF | PAGE 1 | TSR-SAR-87975E602 |
 | Tema GLP-1, Obesity & Cardiometabolic ETF |  |
HRTS (Principal U.S. Listing Exchange: NASDAQ Stock Market LLC)NASDAQ | ||
| Semi-Annual Shareholder Report | August 31, 2024 |
Fund Name | Costs of a $10,000 investment | Costs paid as a percentage of a $10,000 investment* |
| Tema GLP-1, Obesity & Cardiometabolic ETF | $39 | 0.75% |
| * | Annualized. |
Net Assets | $87,841,811 |
Number of Holdings | 45 |
Portfolio Turnover | 29% |
Top 10 Issuers | (% of net assets) |
Amgen, Inc. | 7.1% |
Eli Lilly & Co. | 5.5% |
Alnylam Pharmaceuticals, Inc. | 5.3% |
Vertex Pharmaceuticals, Inc. | 4.4% |
Novo Nordisk AS | 4.4% |
Bridgebio Pharma, Inc. | 4.1% |
Chugai Pharmaceutical Co. Ltd. | 3.7% |
Ultragenyx Pharmaceutical, Inc. | 3.5% |
Cytokinetics, Inc. | 3.3% |
AstraZeneca PLC | 3.1% |
Top Sectors* | (% of net assets) |
Health Care | 97.8% |
Financials | 0.9% |
Cash & Other | 1.3% |
| * | The Global Industry Classification Standard (“GICS®”) was developed by and/or is the exclusive property of MSCI, Inc. (“MSCI”) and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. |
| Tema GLP-1, Obesity & Cardiometabolic ETF | PAGE 1 | TSR-SAR-87975E883 |
| Tema GLP-1, Obesity & Cardiometabolic ETF | PAGE 2 | TSR-SAR-87975E883 |
 | Tema Luxury ETF |  |
LUX (Principal U.S. Listing Exchange: NYSE Arca, Inc.)NYSEArca | ||
| Semi-Annual Shareholder Report | August 31, 2024 |
Fund Name | Costs of a $10,000 investment | Costs paid as a percentage of a $10,000 investment* |
| Tema Luxury ETF | $36 | 0.75% |
| * | Annualized. |
Net Assets | $2,811,112 |
Number of Holdings | 29 |
Portfolio Turnover | 16% |
Top 10 Issuers | (% of net assets) |
Cie Financiere Richemont SA | 9.0% |
Hermes International SCA | 8.4% |
First American Treasury Obligations Fund | 6.6% |
LVMH Moet Hennessy Louis Vuitton SE | 5.3% |
Ferrari NV | 4.9% |
L’Oreal SA | 4.8% |
Pernod Ricard SA | 4.6% |
Hilton Worldwide Holdings, Inc. | 4.5% |
Viking Holdings Ltd. (Ordinary Shares) | 4.5% |
Marriott International, Inc. | 4.2% |
Top Sectors* | (% of net assets) |
Consumer Discretionary | 67.6% |
Consumer Staples | 19.1% |
Management of Companies and Enterprises | 4.5% |
Health Care | 1.7% |
Cash & Other | 7.1% |
| * | The Global Industry Classification Standard (“GICS®”) was developed by and/or is the exclusive property of MSCI, Inc. (“MSCI”) and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. |
| Tema Luxury ETF | PAGE 1 | TSR-SAR-87975E305 |
 | Tema Monopolies and Oligopolies ETF |  |
TOLL (Principal U.S. Listing Exchange: Cboe BZX Exchange, Inc.)CboeBZX | ||
| Semi-Annual Shareholder Report | August 31, 2024 |
Fund Name | Costs of a $10,000 investment | Costs paid as a percentage of a $10,000 investment* |
| Tema Monopolies and Oligopolies ETF | $36 | 0.68% |
| * | Annualized. |
Net Assets | $11,659,645 |
Number of Holdings | 33 |
Portfolio Turnover | 22% |
Top 10 Issuers | (% of net assets) |
Moody’s Corp. | 5.9% |
General Electric Co. | 5.8% |
Intercontinental Exchange, Inc. | 5.6% |
Visa, Inc. | 4.7% |
S&P Global, Inc. | 4.6% |
Fair Isaac Corp. | 4.2% |
Sherwin-Williams Co. | 4.0% |
Teradyne, Inc. | 3.5% |
Tyler Technologies, Inc. | 3.4% |
Equifax, Inc. | 3.4% |
Top Sectors* | (% of net assets) |
Financials | 28.9% |
Industrials | 25.4% |
Information Technology | 24.7% |
Health Care | 12.3% |
Materials | 6.8% |
Cash & Other | 1.9% |
| * | The Global Industry Classification Standard (“GICS®”) was developed by and/or is the exclusive property of MSCI, Inc. (“MSCI”) and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. |
| Tema Monopolies and Oligopolies ETF | PAGE 1 | TSR-SAR-87975E107 |
 | Tema Neuroscience and Mental Health ETF |  |
MNTL (Principal U.S. Listing Exchange: NASDAQ Stock Market LLC)NASDAQ | ||
| Semi-Annual Shareholder Report | August 31, 2024 |
Fund Name | Costs of a $10,000 investment | Costs paid as a percentage of a $10,000 investment* |
| Tema Neuroscience and Mental Health ETF | $39 | 0.75% |
| * | Annualized. |
Net Assets | $12,031,399 |
Number of Holdings | 47 |
Portfolio Turnover | 14% |
Top 10 Issuers | (% of net assets) |
Vertex Pharmaceuticals, Inc. | 6.7% |
Regeneron Pharmaceuticals, Inc. | 5.7% |
Eli Lilly & Co. | 5.6% |
Denali Therapeutics, Inc. | 4.4% |
Argenx SE | 4.3% |
Alnylam Pharmaceuticals, Inc. | 4.1% |
Neurocrine Biosciences, Inc. | 4.1% |
Teva Pharmaceutical Industries Ltd. | 4.0% |
Biogen, Inc. | 3.8% |
UCB SA | 3.5% |
Top Sectors* | (% of net assets) |
Health Care | 99.1% |
Cash & Other | 0.9% |
| * | The Global Industry Classification Standard (“GICS®”) was developed by and/or is the exclusive property of MSCI, Inc. (“MSCI”) and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. |
| Tema Neuroscience and Mental Health ETF | PAGE 1 | TSR-SAR-87975E875 |
 | Tema Oncology ETF |  |
CANC (Principal U.S. Listing Exchange: NASDAQ Stock Market LLC)NASDAQ | ||
| Semi-Annual Shareholder Report | August 31, 2024 |
Fund Name | Costs of a $10,000 investment | Costs paid as a percentage of a $10,000 investment* |
| Tema Oncology ETF | $39 | 0.75% |
| * | Annualized. |
Net Assets | $51,280,837 |
Number of Holdings | 48 |
Portfolio Turnover | 26% |
Top 10 Issuers | (% of net assets) |
Regeneron Pharmaceuticals, Inc. | 6.1% |
AstraZeneca PLC | 5.9% |
Amgen, Inc. | 4.3% |
Merck & Co., Inc. | 4.3% |
Daiichi Sankyo Co. Ltd. | 3.8% |
Argenx SE | 3.7% |
Chugai Pharmaceutical Co. Ltd. | 3.6% |
Blueprint Medicines Corp. | 3.3% |
Illumina, Inc. | 3.3% |
Revolution Medicines, Inc. | 3.1% |
Top Sectors* | (% of net assets) |
Health Care | 99.2% |
Cash & Other | 0.8% |
| * | The Global Industry Classification Standard (“GICS®”) was developed by and/or is the exclusive property of MSCI, Inc. (“MSCI”) and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services. |
| Tema Oncology ETF | PAGE 1 | TSR-SAR-87975E701 |
(b) Note Applicable.
Item 2. Code of Ethics.
Not applicable for semi-annual reports.
Item 3. Audit Committee Financial Expert.
Not applicable for semi-annual reports.
Item 4. Principal Accountant Fees and Services.
Not applicable for semi-annual reports.
Item 5. Audit Committee of Listed Registrants.
Not applicable for semi-annual reports.
Item 6. Investments.
| (a) | Schedule of Investments is included within the financial statements filed under Item 7(a) of this Form. |
| (b) | Not Applicable. |
Item 7. Financial Statements and Financial Highlights for Open-End Investment Companies.
Tema American Reshoring ETF | | RSHO | | NYSE Arca, Inc. | ||||
Tema GP-1, Obesity & Cardiometabolic ETF | | HRTS | | NASDAQ Stock Market LLC | ||||
Tema Luxury ETF | | LUX | | NYSE Arca, Inc. | ||||
Tema Monopolies and Oligopolies ETF | | TOLL | | Cboe BZX Exchange, Inc. | ||||
Tema Neuroscience and Mental Health ETF | | MNTL | | NASDAQ Stock Market LLC | ||||
Tema Oncology ETF | | CANC | | NASDAQ Stock Market LLC | ||||
Page | |||
Shares | Value | |||||
COMMON STOCKS - 99.3% | ||||||
Building Products - 2.6% | ||||||
Allegion PLC | 18,975 | $ 2,634,489 | ||||
Chemicals - 4.4% | ||||||
Linde PLC | 9,350 | 4,471,638 | ||||
Commercial Services & Supplies - 4.9% | ||||||
Clean Harbors, Inc.(a) | 20,158 | 4,956,852 | ||||
Construction & Engineering - 10.0% | ||||||
API Group Corp.(a) | 62,150 | 2,209,432 | ||||
Fluor Corp.(a) | 75,625 | 3,786,544 | ||||
Primoris Services Corp. | 73,175 | 4,129,997 | ||||
10,125,973 | ||||||
Construction Materials - 10.7% | ||||||
CRH PLC | 48,699 | 4,420,408 | ||||
Summit Materials, Inc. - Class A(a) | 67,650 | 2,739,825 | ||||
Vulcan Materials Co. | 14,894 | 3,652,158 | ||||
10,812,391 | ||||||
Electrical Equipment - 13.9% | ||||||
ABB Ltd. | 56,925 | 3,256,588 | ||||
Eaton Corp. PLC | 16,228 | 4,980,860 | ||||
Emerson Electric Co. | 24,475 | 2,579,420 | ||||
Rockwell Automation, Inc. | 12,100 | 3,291,563 | ||||
14,108,431 | ||||||
Ground Transportation - 2.6% | ||||||
Union Pacific Corp. | 10,175 | 2,605,716 | ||||
Hotels, Restaurants & Leisure - 2.5% | ||||||
Compass Group PLC | 79,226 | 2,496,102 | ||||
Life Sciences Tools & Services - 6.3% | ||||||
Danaher Corp. | 11,036 | 2,972,105 | ||||
Lonza Group AG | 5,242 | 3,426,217 | ||||
6,398,322 | ||||||
Machinery - 24.0% | ||||||
Caterpillar, Inc. | 9,350 | 3,329,535 | ||||
Federal Signal Corp. | 38,775 | 3,663,850 | ||||
Ingersoll Rand, Inc. | 47,901 | 4,380,546 | ||||
Parker-Hannifin Corp. | 6,050 | 3,631,210 | ||||
SPX Technologies, Inc.(a) | 28,600 | 4,665,804 | ||||
Terex Corp. | 43,175 | 2,451,045 | ||||
Timken Co. | 26,950 | 2,278,083 | ||||
24,400,073 | ||||||
Metals & Mining - 3.4% | ||||||
ATI, Inc.(a) | 54,450 | 3,478,266 | ||||
Semiconductors & Semiconductor Equipment - 1.3% | ||||||
Taiwan Semiconductor Manufacturing Co. Ltd. - ADR | 7,975 | 1,369,308 | ||||
Shares | Value | |||||
Trading Companies & Distributors - 12.7% | ||||||
Applied Industrial Technologies, Inc. | 26,400 | $5,415,168 | ||||
Fastenal Co. | 37,950 | 2,591,226 | ||||
Herc Holdings, Inc. | 15,700 | 2,298,009 | ||||
WESCO International, Inc. | 15,675 | 2,592,331 | ||||
12,896,734 | ||||||
TOTAL COMMON STOCKS (Cost $92,558,755) | 100,754,295 | |||||
SHORT-TERM INVESTMENTS - 0.7% | ||||||
Money Market Funds - 0.7% | ||||||
First American Treasury Obligations Fund - Class X, 5.18%(b) | 716,078 | 716,078 | ||||
TOTAL SHORT-TERM INVESTMENTS (Cost $716,078) | 716,078 | |||||
TOTAL INVESTMENTS - 100.0% (Cost $93,274,833) | $101,470,373 | |||||
Other Assets in Excess of Liabilities - 0.0%(c) | 36,712 | |||||
TOTAL NET ASSETS - 100.0% | $101,507,085 | |||||
| (a) | Non-income producing security. |
| (b) | The rate shown represents the 7-day annualized effective yield as of August 31, 2024. |
| (c) | Represents less than 0.05% of net assets. |
1 |
Shares | Value | |||||
COMMON STOCKS - 98.7% | ||||||
Biotechnology - 61.1%(a) | ||||||
Akero Therapeutics, Inc.(b) | 43,604 | $ 1,186,029 | ||||
Alnylam Pharmaceuticals, Inc.(b) | 17,730 | 4,657,494 | ||||
Amgen, Inc. | 18,656 | 6,227,932 | ||||
Arcturus Therapeutics Holdings, Inc.(b) | 24,778 | 522,816 | ||||
Arrowhead Pharmaceuticals, Inc.(b) | 66,291 | 1,579,714 | ||||
Ascendis Pharma AS - ADR(b) | 13,466 | 1,864,368 | ||||
Bridgebio Pharma, Inc.(b) | 128,429 | 3,576,748 | ||||
Corbus Pharmaceuticals Holdings, Inc.(b) | 26,295 | 1,608,728 | ||||
Crinetics Pharmaceuticals, Inc.(b) | 50,204 | 2,663,824 | ||||
Cytokinetics, Inc.(b) | 51,073 | 2,915,247 | ||||
Intellia Therapeutics, Inc.(b) | 88,369 | 1,983,000 | ||||
Ionis Pharmaceuticals, Inc.(b) | 52,306 | 2,493,950 | ||||
Keros Therapeutics, Inc.(b) | 28,114 | 1,274,970 | ||||
Madrigal Pharmaceuticals, Inc.(b) | 5,038 | 1,245,041 | ||||
Mereo Biopharma Group PLC - ADR(b) | 526,144 | 2,467,615 | ||||
Mineralys Therapeutics, Inc.(b) | 61,341 | 761,242 | ||||
Mirum Pharmaceuticals, Inc.(b) | 45,226 | 1,949,693 | ||||
Rocket Pharmaceuticals, Inc.(b) | 112,813 | 2,126,525 | ||||
Silence Therapeutics PLC - ADR(b) | 52,342 | 999,209 | ||||
Skye Bioscience, Inc.(b) | 55,540 | 343,793 | ||||
Soleno Therapeutics, Inc.(b) | 14,204 | 695,286 | ||||
Tenaya Therapeutics, Inc.(b) | 171,188 | 458,784 | ||||
Ultragenyx Pharmaceutical, Inc.(b) | 53,648 | 3,046,133 | ||||
Vertex Pharmaceuticals, Inc.(b) | 7,875 | 3,905,134 | ||||
Verve Therapeutics, Inc.(b) | 96,187 | 644,453 | ||||
Viking Therapeutics, Inc.(b) | 18,733 | 1,201,160 | ||||
Zealand Pharma AS(b) | 9,498 | 1,247,755 | ||||
53,646,643 | ||||||
Health Care Equipment & Supplies - 15.1% | ||||||
Boston Scientific Corp.(b) | 26,645 | 2,179,295 | ||||
Dexcom, Inc.(b) | 25,883 | 1,794,727 | ||||
Edwards Lifesciences Corp.(b) | 29,418 | 2,058,083 | ||||
Inari Medical, Inc.(b) | 15,942 | 689,173 | ||||
Insulet Corp.(b) | 12,319 | 2,497,924 | ||||
Masimo Corp.(b) | 14,787 | 1,737,768 | ||||
Medtronic PLC | 26,159 | 2,317,164 | ||||
13,274,134 | ||||||
Insurance - 0.9% | ||||||
Oscar Health, Inc. - Class A(b) | 44,388 | 812,300 | ||||
Life Sciences Tools & Services - 2.2% | ||||||
Gubra AS(b) | 7,620 | 641,389 | ||||
West Pharmaceutical Services, Inc. | 4,120 | 1,292,156 | ||||
1,933,545 | ||||||
Shares | Value | |||||
Pharmaceuticals - 19.4% | ||||||
AstraZeneca PLC | 15,827 | $2,759,083 | ||||
Chugai Pharmaceutical Co. Ltd. | 64,989 | 3,282,569 | ||||
Edgewise Therapeutics, Inc.(b) | 23,641 | 443,269 | ||||
Eli Lilly & Co. | 5,053 | 4,850,981 | ||||
Novartis AG | 9,760 | 1,172,509 | ||||
Novo Nordisk AS | 28,003 | 3,892,890 | ||||
Terns Pharmaceuticals, Inc.(b) | 85,888 | 654,467 | ||||
17,055,768 | ||||||
TOTAL COMMON STOCKS (Cost $78,216,669) | 86,722,390 | |||||
SHORT-TERM INVESTMENTS - 1.3% | ||||||
Money Market Funds - 1.3% | ||||||
First American Treasury Obligations Fund - Class X, 5.18%(c) | 1,105,578 | 1,105,578 | ||||
TOTAL SHORT-TERM INVESTMENTS (Cost $1,105,578) | 1,105,578 | |||||
TOTAL INVESTMENTS - 100.0% (Cost $79,322,247) | $87,827,968 | |||||
Other Assets in Excess of Liabilities - 0.0%(d) | 13,843 | |||||
TOTAL NET ASSETS - 100.0% | $87,841,811 | |||||
| (a) | To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those industries or sectors. |
| (b) | Non-income producing security. |
| (c) | The rate shown represents the 7-day annualized effective yield as of August 31, 2024. |
| (d) | Represents less than 0.05% of net assets. |
2 |
Shares | Value | |||||
COMMON STOCKS - 91.1% | ||||||
Automobiles - 11.0% | ||||||
Bayerische Motoren Werke AG | 792 | $ 73,383 | ||||
Ferrari NV | 276 | 137,114 | ||||
Mercedes-Benz Group AG | 1,452 | 100,058 | ||||
310,555 | ||||||
Beverages - 14.3% | ||||||
Davide Campari-Milano NV | 10,826 | 99,853 | ||||
Kweichow Moutai Co. Ltd. - Class A | 400 | 81,442 | ||||
Pernod Ricard SA | 901 | 128,280 | ||||
Remy Cointreau SA | 1,128 | 92,021 | ||||
401,596 | ||||||
Health Care Equipment & Supplies - 1.7% | ||||||
EssilorLuxottica SA | 206 | 48,776 | ||||
Hotels, Restaurants & Leisure - 14.8% | ||||||
Hilton Worldwide Holdings, Inc. | 576 | 126,512 | ||||
Hyatt Hotels Corp. - Class A | 600 | 91,152 | ||||
Las Vegas Sands Corp. | 828 | 32,284 | ||||
Marriott International, Inc. - Class A | 504 | 118,284 | ||||
MGM Resorts International(a) | 1,260 | 47,363 | ||||
415,595 | ||||||
Leisure Products - 3.6% | ||||||
Sanlorenzo SpA | 2,400 | 100,282 | ||||
Offices of Other Holding Companies - 4.5% | ||||||
Viking Holdings Ltd. (Ordinary Shares)(a) | 3,739 | 125,443 | ||||
Personal Care Products - 4.8% | ||||||
L’Oreal SA | 306 | 134,151 | ||||
Specialty Retail - 0.7% | ||||||
Chow Tai Fook Jewellery Group Ltd. | 25,092 | 21,399 | ||||
Textiles, Apparel & Luxury Goods - 35.7%(b) | ||||||
Brunello Cucinelli SpA | 740 | 72,597 | ||||
Capri Holdings Ltd.(a) | 479 | 17,110 | ||||
Cie Financiere Richemont SA | 1,614 | 254,143 | ||||
Hermes International SCA | 98 | 234,966 | ||||
Lululemon Athletica, Inc.(a) | 333 | 86,403 | ||||
LVMH Moet Hennessy Louis Vuitton SE | 201 | 149,820 | ||||
Moncler SpA | 1,204 | 73,758 | ||||
PRADA SpA | 5,038 | 36,019 | ||||
Ralph Lauren Corp. | 192 | 32,882 | ||||
Samsonite International SA(c) | 17,896 | 45,533 | ||||
1,003,231 | ||||||
TOTAL COMMON STOCKS (Cost $2,802,499) | 2,561,028 | |||||
Shares | Value | |||||
PREFERRED STOCKS - 1.8% | ||||||
Automobiles - 1.8% | ||||||
Dr Ing hc F Porsche AG 0.00%,(c) | 615 | $48,159 | ||||
TOTAL PREFERRED STOCKS (Cost $76,658) | 48,159 | |||||
SHORT-TERM INVESTMENTS - 6.6% | ||||||
Money Market Funds - 6.6% | ||||||
First American Treasury Obligations Fund - Class X, 5.18%(d) | 186,692 | 186,692 | ||||
TOTAL SHORT-TERM INVESTMENTS (Cost $186,692) | 186,692 | |||||
TOTAL INVESTMENTS - 99.5% (Cost $3,065,849) | $2,795,879 | |||||
Other Assets in Excess of Liabilities - 0.5% | 15,233 | |||||
TOTAL NET ASSETS - 100.0% | $2,811,112 | |||||
| (a) | Non-income producing security. |
| (b) | To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those industries or sectors. |
| (c) | Security is exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may only be resold in transactions exempt from registration to qualified institutional investors. As of August 31, 2024, the value of these securities total $93,692 or 3.3% of the Fund’s net assets. |
| (d) | The rate shown represents the 7-day annualized effective yield as of August 31, 2024. |
3 |
Shares | Value | |||||
COMMON STOCKS - 98.1% | ||||||
Aerospace & Defense - 7.4% | ||||||
Airbus SE | 1,162 | $ 178,311 | ||||
General Electric Co. | 3,891 | 679,446 | ||||
857,757 | ||||||
Capital Markets - 21.8% | ||||||
CME Group, Inc. | 1,400 | 302,036 | ||||
Intercontinental Exchange, Inc. | 4,008 | 647,492 | ||||
Moody’s Corp. | 1,411 | 688,201 | ||||
MSCI, Inc. | 651 | 377,964 | ||||
S&P Global, Inc. | 1,037 | 532,230 | ||||
2,547,923 | ||||||
Chemicals - 4.0% | ||||||
Sherwin-Williams Co. | 1,273 | 470,208 | ||||
Commercial Services & Supplies - 3.0% | ||||||
Copart, Inc.(a) | 6,580 | 348,477 | ||||
Construction & Engineering - 2.9% | ||||||
Ferrovial SE | 8,243 | 343,880 | ||||
Construction Materials - 2.8% | ||||||
Vulcan Materials Co. | 1,330 | 326,129 | ||||
Financial Services - 4.7% | ||||||
Visa, Inc. - Class A | 1,979 | 546,936 | ||||
Ground Transportation - 5.2% | ||||||
Canadian National Railway Co. | 2,494 | 293,843 | ||||
Canadian Pacific Kansas City Ltd. | 3,731 | 309,449 | ||||
603,292 | ||||||
Health Care Equipment & Supplies - 1.7% | ||||||
IDEXX Laboratories, Inc.(a) | 406 | 195,420 | ||||
Insurance - 2.4% | ||||||
Aon PLC - Class A | 822 | 282,538 | ||||
Life Sciences Tools & Services - 6.9% | ||||||
Bio-Techne Corp. | 3,194 | 236,324 | ||||
Thermo Fisher Scientific, Inc. | 491 | 301,999 | ||||
Waters Corp.(a) | 753 | 260,802 | ||||
799,125 | ||||||
Machinery - 1.8% | ||||||
Otis Worldwide Corp. | 2,210 | 209,265 | ||||
Pharmaceuticals - 3.7% | ||||||
Merck & Co., Inc. | 1,655 | 196,035 | ||||
Novo Nordisk AS | 1,720 | 239,109 | ||||
435,144 | ||||||
Professional Services - 3.4% | ||||||
Equifax, Inc. | 1,274 | 391,284 | ||||
Shares | Value | |||||
Semiconductors & Semiconductor Equipment - 13.9% | ||||||
ASML Holding NV | 331 | $297,101 | ||||
KLA Corp. | 477 | 390,868 | ||||
Lam Research Corp. | 339 | 278,322 | ||||
Teradyne, Inc. | 2,986 | 408,276 | ||||
Texas Instruments, Inc. | 1,133 | 242,847 | ||||
1,617,414 | ||||||
Software - 10.8% | ||||||
Fair Isaac Corp.(a) | 281 | 486,206 | ||||
Intuit, Inc. | 595 | 375,005 | ||||
Tyler Technologies, Inc.(a) | 683 | 401,515 | ||||
1,262,726 | ||||||
Transportation Infrastructure - 1.7% | ||||||
Aena SME SA(b) | 998 | 201,442 | ||||
TOTAL COMMON STOCKS (Cost $9,580,367) | 11,438,960 | |||||
SHORT-TERM INVESTMENTS - 1.8% | ||||||
Money Market Funds - 1.8% | ||||||
First American Treasury Obligations Fund - Class X, 5.18%(c) | 207,769 | 207,769 | ||||
TOTAL SHORT-TERM INVESTMENTS (Cost $207,769) | 207,769 | |||||
TOTAL INVESTMENTS - 99.9% (Cost $9,788,136) | $11,646,729 | |||||
Other Assets in Excess of Liabilities - 0.1% | 12,916 | |||||
TOTAL NET ASSETS - 100.0% | $11,659,645 | |||||
| (a) | Non-income producing security. |
| (b) | Security is exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may only be resold in transactions exempt from registration to qualified institutional investors. As of August 31, 2024, the value of these securities total $201,442 or 1.7% of the Fund’s net assets. |
| (c) | The rate shown represents the 7-day annualized effective yield as of August 31, 2024. |
4 |
Shares | Value | |||||
COMMON STOCKS - 99.1% | ||||||
Biotechnology - 62.8%(a) | ||||||
ACADIA Pharmaceuticals, Inc.(b) | 10,596 | $ 175,682 | ||||
Alector, Inc.(b) | 14,344 | 75,736 | ||||
Alkermes PLC(b) | 5,940 | 168,993 | ||||
Alnylam Pharmaceuticals, Inc.(b) | 1,880 | 493,857 | ||||
Argenx SE - ADR(b) | 999 | 516,803 | ||||
Avidity Biosciences, Inc.(b) | 2,545 | 111,980 | ||||
Biogen, Inc.(b) | 2,242 | 459,072 | ||||
Biohaven Ltd.(b) | 3,922 | 154,527 | ||||
Catalyst Pharmaceuticals, Inc.(b) | 11,352 | 229,878 | ||||
Crinetics Pharmaceuticals, Inc.(b) | 7,788 | 413,231 | ||||
Day One Biopharmaceuticals, Inc.(b) | 15,820 | 218,949 | ||||
Denali Therapeutics, Inc.(b) | 21,648 | 529,077 | ||||
Dyne Therapeutics, Inc.(b) | 4,717 | 217,406 | ||||
Immunovant, Inc.(b) | 5,866 | 181,259 | ||||
Intellia Therapeutics, Inc.(b) | 11,044 | 247,827 | ||||
Ionis Pharmaceuticals, Inc.(b) | 7,568 | 360,842 | ||||
Neurocrine Biosciences, Inc.(b) | 3,846 | 488,673 | ||||
Prothena Corp. PLC(b) | 10,511 | 234,080 | ||||
PTC Therapeutics, Inc.(b) | 3,124 | 110,340 | ||||
Regeneron Pharmaceuticals, Inc.(b) | 582 | 689,490 | ||||
Sarepta Therapeutics, Inc.(b) | 1,706 | 231,641 | ||||
Scholar Rock Holding Corp.(b) | 7,172 | 66,700 | ||||
Solid Biosciences, Inc.(b) | 8,649 | 77,235 | ||||
Vertex Pharmaceuticals, Inc.(b) | 1,631 | 808,797 | ||||
Voyager Therapeutics, Inc.(b) | 14,960 | 98,138 | ||||
Xenon Pharmaceuticals, Inc.(b) | 4,972 | 200,570 | ||||
7,560,783 | ||||||
Health Care Equipment & Supplies - 11.1% | ||||||
Dexcom, Inc.(b) | 2,148 | 148,942 | ||||
Medtronic PLC | 3,879 | 343,602 | ||||
Penumbra, Inc.(b) | 818 | 165,498 | ||||
Siemens Healthineers AG(c) | 3,045 | 176,981 | ||||
Stryker Corp. | 1,054 | 379,883 | ||||
Sysmex Corp. | 6,108 | 117,823 | ||||
1,332,729 | ||||||
Health Care Providers & Services - 3.5% | ||||||
Acadia Healthcare Co., Inc.(b) | 2,596 | 212,690 | ||||
Option Care Health, Inc.(b) | 4,975 | 159,300 | ||||
Talkspace, Inc.(b) | 26,337 | 52,674 | ||||
424,664 | ||||||
Life Sciences Tools & Services - 0.5% | ||||||
Quanterix Corp.(b) | 4,424 | 57,645 | ||||
Pharmaceuticals - 21.2% | ||||||
Arvinas, Inc.(b) | 3,080 | 80,573 | ||||
Axsome Therapeutics, Inc.(b) | 2,327 | 206,777 | ||||
Eisai Co. Ltd. | 2,036 | 85,220 | ||||
Eli Lilly & Co. | 705 | 676,814 | ||||
Intra-Cellular Therapies, Inc.(b) | 3,388 | 248,273 | ||||
Jazz Pharmaceuticals PLC(b) | 1,672 | 193,918 | ||||
Orion Oyj - Class B | 1,440 | 76,357 | ||||
Shares | Value | |||||
Rapport Therapeutics, Inc.(b) | 3,655 | $79,496 | ||||
Teva Pharmaceutical Industries Ltd. - ADR(b) | 25,662 | 484,242 | ||||
UCB SA | 2,310 | 418,004 | ||||
2,549,674 | ||||||
TOTAL COMMON STOCKS (Cost $11,018,132) | 11,925,495 | |||||
SHORT-TERM INVESTMENTS - 0.9% | ||||||
Money Market Funds - 0.9% | ||||||
First American Treasury Obligations Fund - Class X, 5.18%(d) | 103,584 | 103,584 | ||||
TOTAL SHORT-TERM INVESTMENTS (Cost $103,584) | 103,584 | |||||
TOTAL INVESTMENTS - 100.0% (Cost $11,121,716) | $12,029,079 | |||||
Other Assets in Excess of Liabilities - 0.0%(e) | 2,320 | |||||
TOTAL NET ASSETS - 100.0% | $12,031,399 | |||||
| (a) | To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those industries or sectors. |
| (b) | Non-income producing security. |
| (c) | Security is exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may only be resold in transactions exempt from registration to qualified institutional investors. As of August 31, 2024, the value of these securities total $176,981 or 1.5% of the Fund’s net assets. |
| (d) | The rate shown represents the 7-day annualized effective yield as of August 31, 2024. |
| (e) | Represents less than 0.05% of net assets. |
5 |
Shares | Value | |||||
COMMON STOCKS - 99.2% | ||||||
Biotechnology - 68.6%(a) | ||||||
Agios Pharmaceuticals, Inc.(b) | 22,942 | $1,053,267 | ||||
Amgen, Inc. | 6,571 | 2,193,597 | ||||
Arcellx, Inc.(b) | 11,774 | 809,345 | ||||
Arcus Biosciences, Inc.(b) | 36,514 | 625,120 | ||||
Argenx SE - ADR(b) | 3,663 | 1,894,943 | ||||
BeiGene Ltd. - ADR(b) | 6,364 | 1,220,488 | ||||
Bicycle Therapeutics PLC - ADR(b) | 17,450 | 375,175 | ||||
Blueprint Medicines Corp.(b) | 17,730 | 1,693,924 | ||||
Celldex Therapeutics, Inc.(b) | 26,288 | 1,086,483 | ||||
CG oncology, Inc.(b) | 7,426 | 273,871 | ||||
Cogent Biosciences, Inc.(b) | 46,277 | 497,015 | ||||
Corbus Pharmaceuticals Holdings, Inc.(b) | 10,759 | 658,236 | ||||
CRISPR Therapeutics AG(b) | 23,055 | 1,100,185 | ||||
Cullinan Therapeutics, Inc.(b) | 25,346 | 496,782 | ||||
Day One Biopharmaceuticals, Inc.(b) | 62,339 | 862,772 | ||||
Exact Sciences Corp.(b) | 15,436 | 952,247 | ||||
Exelixis, Inc.(b) | 40,116 | 1,044,219 | ||||
Fate Therapeutics, Inc.(b) | 50,087 | 183,819 | ||||
Genmab AS - ADR(b) | 40,678 | 1,130,848 | ||||
Gilead Sciences, Inc. | 19,597 | 1,548,163 | ||||
Ideaya Biosciences, Inc.(b) | 14,323 | 565,758 | ||||
Immunocore Holdings PLC - ADR(b) | 9,976 | 357,939 | ||||
Incyte Corp.(b) | 21,905 | 1,438,282 | ||||
Intellia Therapeutics, Inc.(b) | 57,199 | 1,283,546 | ||||
Janux Therapeutics, Inc.(b) | 13,124 | 616,565 | ||||
Jasper Therapeutics, Inc.(b) | 11,091 | 241,784 | ||||
Legend Biotech Corp. - ADR(b) | 23,625 | 1,359,619 | ||||
Mereo Biopharma Group PLC - ADR(b) | 311,765 | 1,462,178 | ||||
Merus NV(b) | 12,916 | 658,587 | ||||
Moderna, Inc.(b) | 8,446 | 653,720 | ||||
Nuvalent, Inc. - Class A(b) | 10,357 | 881,691 | ||||
Regeneron Pharmaceuticals, Inc.(b) | 2,626 | 3,110,996 | ||||
Relay Therapeutics, Inc.(b) | 57,620 | 391,240 | ||||
Revolution Medicines, Inc.(b) | 37,646 | 1,604,849 | ||||
SpringWorks Therapeutics, Inc.(b) | 20,144 | 840,206 | ||||
35,167,459 | ||||||
Health Care Equipment & Supplies - 3.0% | ||||||
Lantheus Holdings, Inc.(b) | 7,101 | 756,043 | ||||
Siemens Healthineers AG(c) | 13,212 | 767,907 | ||||
1,523,950 | ||||||
Health Care Providers & Services - 1.6% | ||||||
Guardant Health, Inc.(b) | 32,193 | 823,497 | ||||
Health Care Technology - 1.1% | ||||||
Schrodinger, Inc.(b) | 27,947 | 587,726 | ||||
Life Sciences Tools & Services - 3.3% | ||||||
Illumina, Inc.(b) | 12,780 | 1,679,292 | ||||
Shares | Value | |||||
Pharmaceuticals - 21.6% | ||||||
Arvinas, Inc.(b) | 13,514 | $353,526 | ||||
AstraZeneca PLC | 17,484 | 3,047,944 | ||||
Chugai Pharmaceutical Co. Ltd. | 36,292 | 1,833,095 | ||||
Daiichi Sankyo Co. Ltd. | 46,872 | 1,958,370 | ||||
Merck & Co., Inc. | 18,463 | 2,186,942 | ||||
Novartis AG | 11,305 | 1,358,116 | ||||
Terns Pharmaceuticals, Inc.(b) | 42,951 | 327,287 | ||||
11,065,280 | ||||||
TOTAL COMMON STOCKS (Cost $44,431,821) | 50,847,204 | |||||
SHORT-TERM INVESTMENTS - 0.8% | ||||||
Money Market Funds - 0.8% | ||||||
First American Treasury Obligations Fund - Class X, 5.18%(d) | 431,821 | 431,821 | ||||
TOTAL SHORT-TERM INVESTMENTS (Cost $431,821) | 431,821 | |||||
TOTAL INVESTMENTS - 100.0% (Cost $44,863,642) | $51,279,025 | |||||
Other Assets in Excess of Liabilities - 0.0%(e) | 1,812 | |||||
TOTAL NET ASSETS - 100.0% | $51,280,837 | |||||
| (a) | To the extent that the Fund invests more heavily in a particular industry or sector of the economy, its performance will be especially sensitive to developments that significantly affect those industries or sectors. |
| (b) | Non-income producing security. |
| (c) | Security is exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may only be resold in transactions exempt from registration to qualified institutional investors. As of August 31, 2024, the value of these securities total $767,907 or 1.5% of the Fund’s net assets. |
| (d) | The rate shown represents the 7-day annualized effective yield as of August 31, 2024. |
(e) | Represents less than 0.05% of net assets. |
6 |
Tema American Reshoring ETF | Tema GLP-1, Obesity & Cardiometabolic ETF | Tema Luxury ETF | Tema Monopolies and Oligopolies ETF | Tema Neuroscience and Mental Health ETF | |||||||||||
ASSETS: | |||||||||||||||
Investments, at value | $101,470,373 | $87,827,968 | $2,795,879 | $11,646,729 | $12,029,079 | ||||||||||
Dividends receivable | 94,857 | 64,511 | 16,528 | 5,987 | 1,994 | ||||||||||
Interest receivable | 2,893 | 3,262 | 1,624 | 679 | 604 | ||||||||||
Receivable for investments sold | — | — | — | — | 60,013 | ||||||||||
Receivable for fund shares sold | — | — | — | 333,133 | — | ||||||||||
Foreign currency, at value | — | — | — | — | 7,864 | ||||||||||
Total assets | 101,568,123 | 87,895,741 | 2,814,031 | 11,986,528 | 12,099,554 | ||||||||||
LIABILITIES: | |||||||||||||||
Payable to adviser | 61,038 | 53,930 | 2,919 | 4,339 | 7,479 | ||||||||||
Payable for investments purchased | — | — | — | 322,544 | 60,676 | ||||||||||
Total liabilities | 61,038 | 53,930 | 2,919 | 326,883 | 68,155 | ||||||||||
NET ASSETS | $101,507,085 | $87,841,811 | $2,811,112 | $11,659,645 | $12,031,399 | ||||||||||
NET ASSETS CONSISTS OF: | |||||||||||||||
Paid-in capital | $92,862,318 | $78,116,169 | $3,170,139 | $9,616,243 | $11,120,700 | ||||||||||
Total distributable earnings/ (accumulated losses) | 8,644,767 | 9,725,642 | (359,027) | 2,043,402 | 910,699 | ||||||||||
Total net assets | $101,507,085 | $87,841,811 | $2,811,112 | $11,659,645 | $12,031,399 | ||||||||||
Net assets | $101,507,085 | $87,841,811 | $2,811,112 | $11,659,645 | $12,031,399 | ||||||||||
Shares issued and outstanding(a) | 2,750,000 | 2,490,000 | 120,000 | 350,000 | 440,000 | ||||||||||
Net asset value per share | $36.91 | $35.28 | $23.43 | $33.31 | $27.34 | ||||||||||
COST: | |||||||||||||||
Investments, at cost | $93,274,833 | $79,322,247 | $3,065,849 | $9,788,136 | $11,121,716 | ||||||||||
Foreign currency, at cost | $— | $— | $— | $— | $7,618 | ||||||||||
(a) | Unlimited shares authorized without par value. |
7 |
Tema Oncology ETF | |||
ASSETS: | |||
Investments, at value | $51,279,025 | ||
Receivable for investments sold | 254,022 | ||
Dividends receivable | 35,288 | ||
Interest receivable | 2,266 | ||
Total assets | 51,570,601 | ||
LIABILITIES: | |||
Payable for investments purchased | 258,501 | ||
Payable to adviser | 31,263 | ||
Total liabilities | 289,764 | ||
NET ASSETS | $51,280,837 | ||
NET ASSETS CONSISTS OF: | |||
Paid-in capital | $44,232,132 | ||
Total distributable earnings | 7,048,705 | ||
Total net assets | $51,280,837 | ||
Net assets | $51,280,837 | ||
Shares issued and outstanding(a) | 1,720,000 | ||
Net asset value per share | $29.81 | ||
COST: | |||
Investments, at cost | $44,863,642 | ||
(a) | Unlimited shares authorized without par value. |
8 |
Tema American Reshoring ETF | Tema GLP-1, Obesity & Cardiometabolic ETF | Tema Luxury ETF | Tema Monopolies and Oligopolies ETF | Tema Neuroscience and Mental Health ETF | |||||||||||
INVESTMENT INCOME: | |||||||||||||||
Dividend income | $252,193 | $235,135 | $107,812 | $50,546 | $19,122 | ||||||||||
Less: Dividend withholding taxes | (2,081) | (13,636) | (18,040) | (4,274) | (1,767) | ||||||||||
Interest income | 9,680 | 25,727 | 8,370 | 3,150 | 3,966 | ||||||||||
Total investment income | 259,792 | 247,226 | 98,142 | 49,422 | 21,321 | ||||||||||
EXPENSES: | |||||||||||||||
Investment advisory fee | 232,459 | 339,880 | 36,142 | 34,160 | 56,248 | ||||||||||
Income tax expense | — | — | 10 | — | — | ||||||||||
Total expenses | 232,459 | 339,880 | 36,152 | 34,160 | 56,248 | ||||||||||
Expense waiver by Adviser | (56,499) | (82,573) | (8,864) | (6,319) | (13,665) | ||||||||||
Net expenses | 175,960 | 257,307 | 27,288 | 27,841 | 42,583 | ||||||||||
NET INVESTMENT INCOME/(LOSS) | 83,832 | (10,081) | 70,854 | 21,581 | (21,262) | ||||||||||
REALIZED AND UNREALIZED GAIN/(LOSS) | |||||||||||||||
Net realized gain from: | |||||||||||||||
Investments | 11,620 | 478,644 | 68,400 | 180,232 | 12,276 | ||||||||||
In-kind redemptions | 351,444 | 532,764 | (50,578) | — | — | ||||||||||
Foreign currency transaction | (1,995) | (10,582) | (3,978) | 2,908 | 1 | ||||||||||
Net realized gain | 361,069 | 1,000,826 | 13,844 | 183,140 | 12,277 | ||||||||||
Net change in unrealized appreciation/(depreciation) on: | |||||||||||||||
Investments | 5,363,691 | 3,208,900 | (838,010) | 497,457 | 655,145 | ||||||||||
Foreign currency translation | 120 | 1,057 | 402 | 134 | 282 | ||||||||||
Net change in unrealized appreciation/(depreciation) | 5,363,811 | 3,209,957 | (837,608) | 497,591 | 655,427 | ||||||||||
Net realized and unrealized gain/(loss) | 5,724,880 | 4,210,783 | (823,764) | 680,731 | 667,704 | ||||||||||
NET INCREASE/(DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS | $5,808,712 | $4,200,702 | $(752,910) | $702,312 | $646,442 | ||||||||||
9 |
Tema Oncology ETF | |||
INVESTMENT INCOME: | |||
Dividend income | $110,572 | ||
Less: Dividend withholding taxes | (6,419) | ||
Interest income | 9,290 | ||
Total investment income | 113,443 | ||
EXPENSES: | |||
Investment advisory fee | 151,707 | ||
Total expenses | 151,707 | ||
Expense waiver by Adviser | (36,890) | ||
Net expenses | 114,817 | ||
NET INVESTMENT INCOME/(LOSS) | (1,374) | ||
REALIZED AND UNREALIZED GAIN/(LOSS) | |||
Net realized gain from: | |||
Investments | 219,026 | ||
Foreign currency transaction | (2,494) | ||
Net realized gain | 216,532 | ||
Net change in unrealized appreciation/(depreciation) on: | |||
Investments | 3,538,528 | ||
Foreign currency translation | 1,057 | ||
Net change in unrealized appreciation/(depreciation) | 3,539,585 | ||
Net realized and unrealized gain/(loss) | 3,756,117 | ||
NET INCREASE/(DECREASE) IN NET ASSETS RESULTING FROM OPERATIONS | $3,754,743 | ||
10 |
Tema American Reshoring ETF | Tema GLP-1, Obesity & Cardiometabolic ETF | |||||||||||
Period Ended August 31, 2024 (Unaudited) | Period Ended February 29, 2024(a) | Period Ended August 31, 2024 (Unaudited) | Period Ended February 29, 2024(c) | |||||||||
OPERATIONS: | ||||||||||||
Net investment income/(loss) | $83,832 | $32,909 | $(10,081) | $(16,164) | ||||||||
Net realized gain | 361,069 | 214 | 1,000,826 | 244,496 | ||||||||
Net change in unrealized appreciation | 5,363,811 | 2,831,843 | 3,209,957 | 5,296,608 | ||||||||
Net increase in net assets from operations | 5,808,712 | 2,864,966 | 4,200,702 | 5,524,940 | ||||||||
DISTRIBUTIONS TO SHAREHOLDERS: | ||||||||||||
Distributions to shareholders | — | (28,911) | — | — | ||||||||
Total distributions to shareholders | — | (28,911) | — | — | ||||||||
CAPITAL TRANSACTIONS: | ||||||||||||
Subscriptions | 84,429,341 | 9,790,564(b) | 38,057,682 | 42,373,982 | ||||||||
Redemptions | (1,358,984) | (100,000)(b) | (2,315,495) | — | ||||||||
ETF transaction fees (See Note 7) | — | 1,397 | — | — | ||||||||
Net increase in net assets from capital transactions | 83,070,357 | 9,691,961 | 35,742,187 | 42,373,982 | ||||||||
NET INCREASE IN NET ASSETS | 88,879,069 | 12,528,016 | 39,942,889 | 47,898,922 | ||||||||
NET ASSETS: | ||||||||||||
Beginning of the period | 12,628,016 | 100,000(b) | 47,898,922 | — | ||||||||
End of the period | $101,507,085 | $12,628,016 | $87,841,811 | $47,898,922 | ||||||||
SHARES TRANSACTIONS | ||||||||||||
Subscriptions | 2,420,000 | 370,000 | 1,140,000 | 1,420,000 | ||||||||
Redemptions | (40,000) | (4,000)(b) | (70,000) | — | ||||||||
Total increase in shares outstanding | 2,380,000 | 366,000 | 1,070,000 | 1,420,000 | ||||||||
(a) | Inception date of the Fund was May 11, 2023. |
(b) | Beginning capital of $100,000 was contributed by NEOS Investment Management LLC, investment sub-adviser to the Fund, in exchange for 4,000 Shares of the Fund in connection with the seeding of the Trust. The shares were redeemed by the investment sub-adviser on May 16, 2023. |
(c) | Inception date of the Fund was November 21, 2023. |
11 |
Tema Luxury ETF | Tema Monopolies and Oligopolies ETF | |||||||||||
Period Ended August 31, 2024 (Unaudited) | Period Ended February 29, 2024(a) | Period Ended August 31, 2024 (Unaudited) | Period Ended February 29, 2024(a) | |||||||||
OPERATIONS: | ||||||||||||
Net investment income | $70,854 | $54,956 | $21,581 | $14,813 | ||||||||
Net realized gain/(loss) | 13,844 | (175,881) | 183,140 | (14,449) | ||||||||
Net change in unrealized appreciation/(depreciation) | (837,608) | 568,096 | 497,591 | 1,361,023 | ||||||||
Net increase/(decrease) in net assets from operations | (752,910) | 447,171 | 702,312 | 1,361,387 | ||||||||
DISTRIBUTIONS TO SHAREHOLDERS: | ||||||||||||
Distributions to shareholders | — | (56,013) | — | (20,297) | ||||||||
Return of capital | — | — | — | (4,482) | ||||||||
Total distributions to shareholders | — | (56,013) | — | (24,779) | ||||||||
CAPITAL TRANSACTIONS: | ||||||||||||
Subscriptions | — | 8,053,761 | 3,581,260 | 6,039,465 | ||||||||
Redemptions | (4,884,446) | — | — | — | ||||||||
ETF transaction fees (See Note 7) | — | 3,549 | — | — | ||||||||
Net increase (decrease) in net assets from capital transactions | (4,884,446) | 8,057,310 | 3,581,260 | 6,039,465 | ||||||||
NET INCREASE (DECREASE) IN NET ASSETS | (5,637,356) | 8,448,468 | 4,283,572 | 7,376,073 | ||||||||
NET ASSETS: | ||||||||||||
Beginning of the period | 8,448,468 | — | 7,376,073 | — | ||||||||
End of the period | $2,811,112 | $8,448,468 | $11,659,645 | $7,376,073 | ||||||||
SHARES TRANSACTIONS | ||||||||||||
Subscriptions | — | 330,000 | 110,000 | 240,000 | ||||||||
Redemptions | (210,000) | — | — | — | ||||||||
Total increase/(decrease) in shares outstanding | (210,000) | 330,000 | 110,000 | 240,000 | ||||||||
(a) | Inception date of the Fund was May 11, 2023. |
12 |
Tema Neuroscience and Mental Health ETF | Tema Oncology ETF | |||||||||||
Period Ended August 31, 2024 (Unaudited) | Period Ended February 29, 2024(a) | Period Ended August 31, 2024 (Unaudited) | Period Ended February 29, 2024(b) | |||||||||
OPERATIONS: | ||||||||||||
Net investment loss | $(21,262) | $(5,403) | $(1,374) | $(10,779) | ||||||||
Net realized gain | 12,277 | 17,442 | 216,532 | 526,500 | ||||||||
Net change in unrealized appreciation | 655,427 | 252,218 | 3,539,585 | 2,876,655 | ||||||||
Net increase in net assets from operations | 646,442 | 264,257 | 3,754,743 | 3,392,376 | ||||||||
DISTRIBUTIONS TO SHAREHOLDERS: | ||||||||||||
Distributions to shareholders | — | — | — | (98,414) | ||||||||
Total distributions to shareholders | — | — | — | (98,414) | ||||||||
CAPITAL TRANSACTIONS: | ||||||||||||
Subscriptions | — | 11,120,700 | 28,646,244 | 15,585,888 | ||||||||
Net increase in net assets from capital transactions | — | 11,120,700 | 28,646,244 | 15,585,888 | ||||||||
NET INCREASE IN NET ASSETS | 646,442 | 11,384,957 | 32,400,987 | 18,879,850 | ||||||||
NET ASSETS: | ||||||||||||
Beginning of the period | 11,384,957 | — | 18,879,850 | — | ||||||||
End of the period | $12,031,399 | $11,384,957 | $51,280,837 | $18,879,850 | ||||||||
SHARES TRANSACTIONS | ||||||||||||
Subscriptions | — | 440,000 | 1,050,000 | 670,000 | ||||||||
Total increase in shares outstanding | — | 440,000 | 1,050,000 | 670,000 | ||||||||
(a) | Inception date of the Fund was January 23, 2024. |
(b) | Inception date of the Fund was August 15, 2023. |
13 |
Period Ended August 31, 2024 (Unaudited) | Period Ended February 29, 2024(a) | |||||
PER SHARE DATA: | ||||||
Net asset value, beginning of period | $34.13 | $25.00 | ||||
INVESTMENT OPERATIONS: | ||||||
Net investment income(b) | 0.06 | 0.10 | ||||
Net realized and unrealized gain on investments(c) | 2.72 | 9.11 | ||||
Total from investment operations | 2.78 | 9.21 | ||||
LESS DISTRIBUTIONS FROM: | ||||||
From net investment income | — | (0.08) | ||||
Total distributions | — | (0.08) | ||||
ETF transaction fees per share | — | 0.00(d) | ||||
Net asset value, end of period | $36.91 | $34.13 | ||||
TOTAL RETURN(e) | 8.15% | 36.88% | ||||
SUPPLEMENTAL DATA AND RATIOS: | ||||||
Net assets, end of period (in thousands) | $101,507 | $12,628 | ||||
Ratio of expenses to average net assets: | ||||||
Before expense reimbursement/recoupment(f) | 0.99% | 0.99% | ||||
After expense reimbursement/recoupment(f) | 0.75% | 0.75% | ||||
Ratio of net investment income to average net assets(f) | 0.36% | 0.43% | ||||
Portfolio turnover rate(e)(g) | 4% | —% | ||||
(a) | Inception date of the Fund was May 11, 2023. |
(b) | Net investment income per share has been calculated based on average shares outstanding during the period. |
(c) | Realized and unrealized gains and losses per share in the caption are balancing amounts necessary to reconcile the change in net asset value per share for the period, and may not reconcile with the aggregate gains and losses in the Statement of Operations due to share transactions for the period. |
(d) | Amount represents less than $0.005 per share. |
(e) | Not annualized for periods less than one year. |
(f) | Annualized for periods less than one year. |
(g) | Portfolio turnover rate excludes in-kind transactions. |
14 |
Period Ended August 31, 2024 (Unaudited) | Period Ended February 29, 2024(a) | |||||
PER SHARE DATA: | ||||||
Net asset value, beginning of period | $33.73 | $26.47 | ||||
INVESTMENT OPERATIONS: | ||||||
Net investment loss(b) | (0.00)(c) | (0.02) | ||||
Net realized and unrealized gain on investments(d) | 1.55 | 7.28 | ||||
Total from investment operations | 1.55 | 7.26 | ||||
LESS DISTRIBUTIONS FROM: | ||||||
Total distributions | — | — | ||||
Net asset value, end of period | $35.28 | $33.73 | ||||
TOTAL RETURN(e) | 4.58% | 27.43% | ||||
SUPPLEMENTAL DATA AND RATIOS: | ||||||
Net assets, end of period (in thousands) | $87,842 | $47,899 | ||||
Ratio of expenses to average net assets: | ||||||
Before expense reimbursement/recoupment(f) | 0.99% | 0.99% | ||||
After expense reimbursement/recoupment(f) | 0.75% | 0.75% | ||||
Ratio of net investment loss to average net assets(f) | (0.03)% | (0.25)% | ||||
Portfolio turnover rate(e)(g) | 29% | 8% | ||||
(a) | Inception date of the Fund was November 21, 2023. |
(b) | Net investment income per share has been calculated based on average shares outstanding during the period. |
(c) | Amount represents less than $0.005 per share. |
(d) | Realized and unrealized gains and losses per share in the caption are balancing amounts necessary to reconcile the change in net asset value per share for the periods, and may not reconcile with the aggregate gains and losses in the Statement of Operations due to share transactions for the period. |
(e) | Not annualized for periods less than one year. |
(f) | Annualized for periods less than one year. |
(g) | Portfolio turnover rate excludes in-kind transactions. |
15 |
Period Ended August 31, 2024 (Unaudited) | Period Ended February 29, 2024(a) | |||||
PER SHARE DATA: | ||||||
Net asset value, beginning of period | $25.60 | $25.00 | ||||
INVESTMENT OPERATIONS: | ||||||
Net investment income(b) | 0.24 | 0.18 | ||||
Net realized and unrealized gain (loss) on investments(c) | (2.41) | 0.58 | ||||
Total from investment operations | (2.17) | 0.76 | ||||
LESS DISTRIBUTIONS FROM: | ||||||
From net investment income | — | (0.17) | ||||
Total distributions | — | (0.17) | ||||
ETF transaction fees per share | — | 0.01 | ||||
Net asset value, end of period | $23.43 | $25.60 | ||||
TOTAL RETURN(d) | −8.49% | 3.15% | ||||
SUPPLEMENTAL DATA AND RATIOS: | ||||||
Net assets, end of period (in thousands) | $2,811 | $8,448 | ||||
Ratio of expenses to average net assets: | ||||||
Before expense reimbursement/recoupment(e) | 0.99% | 0.99% | ||||
After expense reimbursement/recoupment(e) | 0.75% | 0.75% | ||||
Ratio of net investment income to average net assets(e) | 1.94% | 0.97% | ||||
Portfolio turnover rate(d)(f) | 16% | 29% | ||||
(a) | Inception date of the Fund was May 11, 2023. |
(b) | Net investment income per share has been calculated based on average shares outstanding during the period. |
(c) | Realized and unrealized gains and losses per share in the caption are balancing amounts necessary to reconcile the change in net asset value per share for the periods, and may not reconcile with the aggregate gains and losses in the Statement of Operations due to share transactions for the period. |
(d) | Not annualized for periods less than one year. |
(e) | Annualized for periods less than one year. |
(f) | Portfolio turnover rate excludes in-kind transactions. |
16 |
Period Ended August 31, 2024 (Unaudited) | Period Ended February 29, 2024(a) | |||||
PER SHARE DATA: | ||||||
Net asset value, beginning of period | $30.73 | $25.00 | ||||
INVESTMENT OPERATIONS: | ||||||
Net investment income(b) | 0.08 | 0.07 | ||||
Net realized and unrealized gain on investments(c) | 2.50 | 5.76 | ||||
Total from investment operations | 2.58 | 5.83 | ||||
LESS DISTRIBUTIONS FROM: | ||||||
From net investment income | — | (0.08) | ||||
Return of capital | — | (0.02) | ||||
Total distributions | — | (0.10) | ||||
Net asset value, end of period | $33.31 | $30.73 | ||||
TOTAL RETURN(d) | 8.40% | 23.38% | ||||
SUPPLEMENTAL DATA AND RATIOS: | ||||||
Net assets, end of period (in thousands) | $11,660 | $7,376 | ||||
Ratio of expenses to average net assets: | ||||||
Before expense reimbursement/recoupment(e) | 0.83% | 0.99% | ||||
After expense reimbursement/recoupment(e) | 0.68% | 0.75% | ||||
Ratio of net investment income to average net assets(e) | 0.52% | 0.31% | ||||
Portfolio turnover rate(d)(f) | 22% | 6% | ||||
(a) | Inception date of the Fund was May 11, 2023. |
(b) | Net investment income per share has been calculated based on average shares outstanding during the period. |
(c) | Realized and unrealized gains and losses per share in the caption are balancing amounts necessary to reconcile the change in net asset value per share for the period, and may not reconcile with the aggregate gains and losses in the Statement of Operations due to share transactions for the period. |
(d) | Not annualized for periods less than one year. |
(e) | Annualized for periods less than one year. |
(f) | Portfolio turnover rate excludes in-kind transactions. |
17 |
Period Ended August 31, 2024 (Unaudited) | Period Ended February 29, 2024(a) | |||||
PER SHARE DATA: | ||||||
Net asset value, beginning of period | $25.87 | $25.35 | ||||
INVESTMENT OPERATIONS: | ||||||
Net investment loss(b) | (0.05) | (0.02) | ||||
Net realized and unrealized gain on investments(c) | 1.52 | 0.54 | ||||
Total from investment operations | 1.47 | 0.52 | ||||
LESS DISTRIBUTIONS FROM: | ||||||
Total distributions | — | — | ||||
Net asset value, end of period | $27.34 | $25.87 | ||||
TOTAL RETURN(d) | 5.68% | 2.07% | ||||
SUPPLEMENTAL DATA AND RATIOS: | ||||||
Net assets, end of period (in thousands) | $12,031 | $11,385 | ||||
Ratio of expenses to average net assets: | ||||||
Before expense reimbursement/recoupment(e) | 0.99% | 0.99% | ||||
After expense reimbursement/recoupment(e) | 0.75% | 0.75% | ||||
Ratio of net investment loss to average net assets(e) | (0.37)% | (0.58)% | ||||
Portfolio turnover rate(d)(f) | 14% | 2% | ||||
(a) | Inception date of the Fund was January 23, 2024. |
(b) | Net investment income per share has been calculated based on average shares outstanding during the period. |
(c) | Realized and unrealized gains and losses per share in the caption are balancing amounts necessary to reconcile the change in net asset value per share for the periods, and may not reconcile with the aggregate gains and losses in the Statement of Operations due to share transactions for the period. |
(d) | Not annualized for periods less than one year. |
(e) | Annualized for periods less than one year. |
(f) | Portfolio turnover rate excludes in-kind transactions. |
18 |
Period Ended August 31, 2024 (Unaudited) | Period Ended February 29, 2024(a) | |||||
PER SHARE DATA: | ||||||
Net asset value, beginning of period | $28.18 | $25.12 | ||||
INVESTMENT OPERATIONS: | ||||||
Net investment loss(b) | (0.00)(c) | (0.03) | ||||
Net realized and unrealized gain on investments(d) | 1.63 | 3.23 | ||||
Total from investment operations | 1.63 | 3.20 | ||||
LESS DISTRIBUTIONS FROM: | ||||||
From net investment income | — | (0.13) | ||||
From net realized gains | — | (0.01) | ||||
Total distributions | — | (0.14) | ||||
Net asset value, end of period | $29.81 | $28.18 | ||||
TOTAL RETURN(e) | 5.81% | 12.84% | ||||
SUPPLEMENTAL DATA AND RATIOS: | ||||||
Net assets, end of period (in thousands) | $51,281 | $18,880 | ||||
Ratio of expenses to average net assets: | ||||||
Before expense reimbursement/recoupment(f) | 0.99% | 0.99% | ||||
After expense reimbursement/recoupment(f) | 0.75% | 0.75% | ||||
Ratio of net investment loss to average net assets(f) | (0.01)% | (0.18)% | ||||
Portfolio turnover rate(e)(g) | 26% | 26% | ||||
(a) | Inception date of the Fund was August 15, 2023. |
(b) | Net investment income per share has been calculated based on average shares outstanding during the period. |
(c) | Amount represents less than $0.005 per share. |
(d) | Realized and unrealized gains and losses per share in the caption are balancing amounts necessary to reconcile the change in net asset value per share for the periods, and may not reconcile with the aggregate gains and losses in the Statement of Operations due to share transactions for the period. |
(e) | Not annualized for periods less than one year. |
(f) | Annualized for periods less than one year. |
(g) | Portfolio turnover rate excludes in-kind transactions. |
19 |
| A. | Investment Valuation. The net asset value (“NAV”) of each Fund’s shares is calculated each business day as of the close of regular trading on the New York Stock Exchange (“NYSE”), generally 4:00 p.m., Eastern Time. NAV per share is computed by dividing the net assets of each Fund by each Fund’s number of shares outstanding. |
20 |
| Level 1 – | Quoted prices in active markets for identical assets that the Funds have the ability to access. |
| Level 2 – | Other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). |
| Level 3 – | Significant unobservable inputs (including the Funds’ own assumptions in determining the fair value of investments). |
Level 1 | Level 2 | Level 3 | Total | |||||||||
Investments: | ||||||||||||
Common Stocks | $100,754,295 | $ — | $ — | $100,754,295 | ||||||||
Money Market Funds | 716,078 | — | — | 716,078 | ||||||||
Total Investments | $101,470,373 | $— | $— | $101,470,373 | ||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||
Investments: | ||||||||||||
Common Stocks | $ 86,722,390 | $ — | $ — | $ 86,722,390 | ||||||||
Money Market Funds | 1,105,578 | — | — | 1,105,578 | ||||||||
Total Investments | $87,827,968 | $— | $— | $87,827,968 | ||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||
Investments: | ||||||||||||
Common Stocks | $ 2,561,028 | $ — | $ — | $ 2,561,028 | ||||||||
Preferred Stocks | 48,159 | — | — | 48,159 | ||||||||
Money Market Funds | 186,692 | — | — | 186,692 | ||||||||
Total Investments | $2,795,879 | $— | $— | $2,795,879 | ||||||||
21 |
Level 1 | Level 2 | Level 3 | Total | |||||||||
Investments: | ||||||||||||
Common Stocks | $ 11,438,960 | $ — | $ — | $ 11,438,960 | ||||||||
Money Market Funds | 207,769 | — | — | 207,769 | ||||||||
Total Investments | $11,646,729 | $— | $— | $11,646,729 | ||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||
Investments: | ||||||||||||
Common Stocks | $ 11,925,495 | $ — | $ — | $ 11,925,495 | ||||||||
Money Market Funds | 103,584 | — | — | 103,584 | ||||||||
Total Investments | $12,029,079 | $— | $— | $12,029,079 | ||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||
Investments: | ||||||||||||
Common Stocks | $ 50,847,204 | $ — | $ — | $ 50,847,204 | ||||||||
Money Market Funds | 431,821 | — | — | 431,821 | ||||||||
Total Investments | $51,279,025 | $— | $— | $51,279,025 | ||||||||
| B. | Foreign Currency Translation. The books and records of the Funds are maintained in U.S. dollars. The Funds’ assets and liabilities in foreign currencies are translated into U.S. dollars at the prevailing exchange rate at the valuation date. Transactions denominated in foreign currencies are translated into U.S. dollars at the prevailing exchange rate on the date of the transaction. The Funds’ income earned and expenses incurred in foreign denominated currencies are translated into U.S. dollars at the prevailing exchange rate on the date of such activity. |
| C. | Use of Estimates. The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statement. Actual results could differ from those estimates. |
22 |
| D. | Federal Income Taxes. Each Fund intends to qualify as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code of 1986, as amended. If so qualified, the Funds will not be subject to federal income tax to the extent each Fund distributes substantially all its taxable net investment income and net capital gains to its shareholders. Therefore, no provision for federal income tax should be required. Management of the Funds is required to determine whether a tax position taken by the Funds is more likely than not to be sustained upon examination by the applicable taxing authority. Based on its analysis, Management has concluded that there are no significant uncertain tax positions that would require recognition in the financial statements as of the fiscal period ended August 31, 2024. The Funds recognize interest and penalties, if any, related to unrecognized tax benefits as income tax expense on the Statements of Operations. Management of the Funds are required to determine whether a tax position taken by the Funds is more likely than not to be sustained upon examination by the applicable taxing authority. Based on its analysis, Management has concluded that the Funds do not have any unrecognized tax benefits or uncertain tax positions that would require a provision for income tax. Accordingly, the Funds did not incur any interest or penalties for the period ended August 31, 2024. |
| E. | Distributions to Shareholders. Each Fund expects to declare and distribute all of its net investment income, if any, to shareholders as dividends at least annually. The Funds will distribute net realized capital gains, if any, annually. The Funds may distribute such income dividends and capital gains more frequently, if necessary, to reduce or eliminate federal excise or income taxes on the Funds. The amount of any distribution will vary, and there is no guarantee the Funds will pay either an income dividend or a capital gains distribution. |
| F. | Reclassification of Capital Accounts. GAAP requires that certain components of net assets relating to permanent differences be reclassified between financial and tax reporting. These reclassifications have no effect on net assets or NAV per share and are primarily due to differing book and tax treatments for in-kind redemptions. For the period ended February 29, 2024, the following adjustments were made: |
Distributable Earnings (Accumulated Loss) | Paid-in Capital | |||||
Tema American Reshoring ETF | $— | $— | ||||
Tema GP-1, Obesity & Cardiometabolic ETF | $— | $— | ||||
Tema Luxury ETF | $2,725 | $(2,725 ) | ||||
Tema Monopolies and Oligopolies ETF | $— | $— | ||||
Tema Neuroscience and Mental Health ETF | $— | $— | ||||
Tema Oncology ETF | $— | $— | ||||
23 |
Management fees | |||
Tema American Reshoring ETF | $232,459 | ||
Tema GP-1, Obesity & Cardiometabolic ETF | $339,880 | ||
Tema Luxury ETF | $36,142 | ||
Tema Monopolies and Oligopolies ETF | $34,160 | ||
Tema Neuroscience and Mental Health ETF | $56,248 | ||
Tema Oncology ETF | $151,707 | ||
24 |
Expires February 28, 2028 | Expires February 28, 2027 | |||||
Tema American Reshoring ETF | $56,499 | $18,237 | ||||
Tema GP-1, Obesity & Cardiometabolic ETF | $82,573 | $15,517 | ||||
Tema Luxury ETF | $8,864 | $13,558 | ||||
Tema Monopolies and Oligopolies ETF* | $6,319 | $11,618 | ||||
Tema Neuroscience and Mental Health ETF | $13,665 | $2,218 | ||||
Tema Oncology ETF | $36,890 | $14,178 | ||||
| * | Contractual waiver for Fund was removed effective July 1, 2024. |
25 |
Purchases | Sales | |||||
Tema American Reshoring ETF | $2,280,142 | $2,116,040 | ||||
Tema GP-1, Obesity & Cardiometabolic ETF | 20,435,109 | 20,014,526 | ||||
Tema Luxury ETF | 1,023,773 | 1,548,123 | ||||
Tema Monopolies and Oligopolies ETF | 1,952,334 | 1,860,224 | ||||
Tema Neuroscience and Mental Health ETF | 1,587,246 | 1,555,752 | ||||
Tema Oncology ETF | 8,543,836 | 8,270,965 | ||||
Purchases In-Kind | Sales In-Kind | |||||
Tema American Reshoring ETF | $83,662,814 | $1,347,555 | ||||
Tema GP-1, Obesity & Cardiometabolic ETF | 37,238,599 | 2,279,261 | ||||
Tema Luxury ETF | — | 4,305,113 | ||||
Tema Monopolies and Oligopolies ETF | 3,469,214 | — | ||||
Tema Neuroscience and Mental Health ETF | — | — | ||||
Tema Oncology ETF | 28,143,546 | — | ||||
Period Ended August 31, 2024 | Period Ended February 29, 2024 | ||||||||
Ordinary Income | Ordinary Income | Return of Capital | |||||||
Tema American Reshoring ETF | $ — | $28,911 | $— | ||||||
Tema GP-1, Obesity & Cardiometabolic ETF | — | — | — | ||||||
Tema Luxury ETF | — | 56,013 | — | ||||||
Tema Monopolies and Oligopolies ETF | — | 20,297 | 4,482 | ||||||
Tema Neuroscience and Mental Health ETF | — | — | — | ||||||
Tema Oncology ETF | — | 98,414 | — | ||||||
Indefinite Short-Term Losses | Indefinite Long-Term Losses | Total | |||||||
Tema American Reshoring ETF | $1 | $ — | $1 | ||||||
Tema GP-1, Obesity & Cardiometabolic ETF | — | — | — | ||||||
Tema Luxury ETF | 162,637 | — | 162,637 | ||||||
Tema Monopolies and Oligopolies ETF | 17,063 | — | 17,063 | ||||||
Tema Neuroscience and Mental Health ETF | — | — | — | ||||||
Tema Oncology ETF | — | — | — | ||||||
26 |
Tema American Reshoring ETF | Tema GP-1, Obesity & Cardiometabolic ETF | Tema Luxury ETF | Tema Monopolies and Oligopolies ETF | Tema Neuroscience and Mental Health ETF | Tema Oncology ETF | |||||||||||||
Federal income tax cost of investments* | $9,789,654 | $42,810,476 | $8,138,387 | $5,952,265 | $11,137,881 | $16,864,244 | ||||||||||||
Aggregate gross unrealized appreciation | 2,903,167 | 6,371,347 | 916,106 | 1,375,808 | 656,316 | 2,746,905 | ||||||||||||
Aggregate gross unrealized (depreciation) | (71,324 ) | (1,536,331 ) | (359,586 ) | (15,039 ) | (404,098 ) | (734,684 ) | ||||||||||||
Net unrealized appreciation (depreciation) | 2,831,843 | 4,835,016 | 556,520 | 1,360,769 | 252,218 | 2,012,221 | ||||||||||||
Undistributed Ordinary Income | 4,213 | 689,924 | — | — | 12,039 | 1,281,741 | ||||||||||||
Undistributed Long Term Capital Gains | — | — | — | — | — | — | ||||||||||||
Distributable Earnings | 4,213 | 689,924 | — | — | 12,039 | 1,281,741 | ||||||||||||
Accumulated capital and other gain/(loss) | (1) | — | (162,637) | (19,679 ) | — | — | ||||||||||||
Total distributable earnings (accumulated loss) | $2,836,055 | $5,524,940 | $393,883 | $1,341,090 | $264,257 | $3,293,962 | ||||||||||||
| * | Represents cost for federal income tax purposes and differs from the cost for financial reporting purposes due to wash sales and passive foreign investment companies (PFICs). |
27 |
Variable Rate Transaction Fees | |||
Tema American Reshoring ETF | $ — | ||
Tema GP-1, Obesity & Cardiometabolic ETF | — | ||
Tema Luxury ETF | — | ||
Tema Monopolies and Oligopolies ETF | — | ||
Tema Neuroscience and Mental Health ETF | — | ||
Tema Oncology ETF | — | ||
28 |
Tema American Reshoring ETF | 100.00% | ||
Tema GP-1, Obesity & Cardiometabolic ETF | 0.00% | ||
Tema Luxury ETF | 93.86% | ||
Tema Monopolies and Oligopolies ETF | 100.00% | ||
Tema Neuroscience and Mental Health ETF | 0.00% | ||
Tema Oncology ETF | 2.40% | ||
Tema American Reshoring ETF | 100.00% | ||
Tema GP-1, Obesity & Cardiometabolic ETF | 0.00% | ||
Tema Luxury ETF | 13.21% | ||
Tema Monopolies and Oligopolies ETF | 100.00% | ||
Tema Neuroscience and Mental Health ETF | 0.00% | ||
Tema Oncology ETF | 1.38% | ||
Tema American Reshoring ETF | 0.00% | ||
Tema GP-1, Obesity & Cardiometabolic ETF | 0.00% | ||
Tema Luxury ETF | 0.00% | ||
Tema Monopolies and Oligopolies ETF | 0.00% | ||
Tema Neuroscience and Mental Health ETF | 0.00% | ||
Tema Oncology ETF | 9.98% | ||
Fund | Gross Foreign Source Income | Foreign Taxes Passthrough | Gross Foreign Source Income | Foreign Taxes Passthrough | Shares Outstanding at 2/29/2024 | ||||||||||
Tema Luxury ETF | $59,248 | $7,224 | $0.18 | $0.02 | 330,000 | ||||||||||
29 |
30 |
31 |
32 |
33 |
34 |
(b) Financial Highlights are included within the financial statements filed under Item 7(a) of this Form.
Item 8. Changes in and Disagreements with Accountants for Open-End Investment Companies.
Response included within Item 7(a) of this Form.
Item 9. Proxy Disclosure for Open-End Investment Companies.
Response included within Item 7(a) of this Form.
Item 10. Remuneration Paid to Directors, Officers, and Others of Open-End Investment Companies.
Response included within Item 7(a) of this Form.
Item 11. Statement Regarding Basis for Approval of Investment Advisory Contract.
Response included within Item 7(a) of this Form.
Item 12. Disclosure of Proxy Voting Policies and Procedures for Closed-End Management Investment Companies.
Not applicable to open-end investment companies.
Item 13. Portfolio Managers of Closed-End Management Investment Companies.
Not applicable to open-end investment companies.
Item 14. Purchases of Equity Securities by Closed-End Management Investment Company and Affiliated Purchasers.
Not applicable to open-end investment companies.
Item 15. Submission of Matters to a Vote of Security Holders.
There have been no material changes to the procedures by which shareholders may recommend nominees to the registrant’s board of trustees.
Item 16. Controls and Procedures.
(a) The Registrant’s Principal Executive Officer and Principal Financial Officer have reviewed the Registrant’s disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940 (the “Act”)) as of a date within 90 days of the filing of this report, as required by Rule 30a-3(b) under the Act and Rules 13a-15(b) or 15d-15(b) under the Securities Exchange Act of 1934. Based on their review, such officers have concluded that the disclosure controls and procedures are effective in ensuring that information required to be disclosed in this report is appropriately recorded, processed, summarized and reported and made known to them by others within the Registrant and by the Registrant’s service provider.
(b) There were no changes in the Registrant’s internal control over financial reporting (as defined in Rule 30a-3(d) under the Act) that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, the Registrant’s internal control over financial reporting.
Item 17. Disclosure of Securities Lending Activities for Closed-End Management Investment Companies.
Not applicable to open-end investment companies.
Item 18. Recovery of Erroneously Awarded Compensation.
(a) Not Applicable.
(b) Not Applicable.
Item 19. Exhibits.
(a) (1) Any code of ethics or amendment thereto, that is the subject of the disclosure required by Item 2, to the extent that the registrant intends to satisfy Item 2 requirements through filing an exhibit. Not Applicable.
(2) Any policy required by the listing standards adopted pursuant to Rule 10D-1 under the Exchange Act (17 CFR 240.10D-1) by the registered national securities exchange or national securities association upon which the registrant’s securities are listed. Not Applicable.
(b) Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Furnished herewith.
(4) Any written solicitation to purchase securities under Rule 23c-1 under the Act sent or given during the period covered by the report by or on behalf of the registrant to 10 or more persons. Not applicable to open-end investment companies.
(5) Change in the registrant’s independent public accountant. Provide the information called for by Item 4 of Form 8-K under the Exchange Act (17 CFR 249.308). Unless otherwise specified by Item 4, or related to and necessary for a complete understanding of information not previously disclosed, the information should relate to events occurring during the reporting period. Not applicable to open-end investment companies and ETFs.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Tema ETF Trust | |||
| By | /s/ Matthew Keeling | ||
Matthew Keeling President/Principal Executive Officer | |||
| Date | 10/22/2024 |
Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| By | /s/ Matthew Keeling | ||
Matthew Keeling President/Principal Executive Officer |
| Date | 10/22/2024 |
| By | /s/ Josh Hunter | ||
Josh Hunter Treasurer/Principal Financial Officer |
| Date | 10/22/2024 |
